Work

Efficacy and Safety of Biosimilar Insulin Aspart (Rapilin®) Versus Originator (NovoRapid®) in Type 1 Diabetes: A Multicenter, Retrospective Cohort Study

Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Data on the biosimilar insulin aspart Rapilin® ("Biosimilar") in patients with T1DM, particularly in children and adolescents, remain scarce. This study compared the real-world efficacy and safety of Biosimilar and the originator insulin aspart NovoRapid® ("Originator") in patients with type 1 diabetes mellitus (T1DM). METHODS: Electronic medical records from 34 hospitals in China covering the period from January 1, 2023 to January 31, 2026 served as the data source for this multicenter, retrospective cohort study. A total of 229 patients with T1DM who had been receiving continuous Biosimilar (n = 116) or Originator (n = 113) treatment for ≥ 12 weeks were included. The primary endpoint was the change in glycated hemoglobin (HbA1c) from baseline to the last measurement before January 31, 2026. Treatment-emergent adverse events (TEAEs) were collected and classified. RESULTS: Of the 229 included patients, 112 (48.9%) were men. The Biosimilar and the Originator groups had a mean age of 24.88 ± 17.73 years and 30.69 ± 20.84 years, respectively. The Biosimilar and the Originator groups had significant and comparable HbA1c reduction from baseline (adjusted least squares means - 1.90% vs - 1.59%; difference - 0.32%, 95% confidence interval [- 0.94%, 0.31%], P = 0.322). Furthermore, the Biosimilar group showed a marginally significant trend toward a higher HbA1c target (< 7.0%) achievement rate than the Originator group (P = 0.056). Changes in fasting blood glucose, total daily insulin dose, and daily prandial insulin dose were comparable between groups. The incidences of TEAEs (37.1% vs 38.9%), including level 1 to 3 hypoglycemia and diabetic ketoacidosis, were comparable between the Biosimilar and Originator groups. However, patients receiving Biosimilar had significantly lower incidence of injection-site reactions than patients receiving Originator (0.0% vs 5.3%, P = 0.014). CONCLUSION: Biosimilar showed comparable glycemic control, dose stability, and systemic safety to Originator in a diverse T1DM cohort containing a substantial proportion (50.0%) of pediatric and adolescent patients.
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $7,400
OpenAlex ID: W7225860527
FWCI:
Cites: 14
Cited by:
Related to: 10